Test Code LAB1234683 BCR-ABL1 Standard p210, p190
Useful For
Useful for diagnosis and monitoring of Philadelphia chromosome-positive cases of CML and ALL. Also useful for monitoring minimal residual disease (MRD) for ALL and AML.
Performing Laboratory
NeoGenomics
Specimen Required
Bone Marrow: 2 mL EDTA tube. Sodium heparin acceptable.
Peripheral Blood: 5 mL EDTA tube. Sodium heparin acceptable.
Specimen Stability Information
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <7 days old preferred.
Reject Due To
Specimens lacking two patient identifiers
- Patient’s first and Last name
- Patient’s Date of Birth
Day(s) Performed
7 days from reciept at performing laboratory.
Method Name
Molecular
CPT Code Information
81206
81207
Clinical Information
Real-time RT-PCR for quantitative detection of t(9;22) BCR-ABL1 fusion transcripts that result in major p210 (e13a2 and/or e14a2) or minor p190 (e1a2) fusion proteins with option to add p230 detection (micro or atypical variant). Analytical sensitivity is 0.002% for p210 and 0.005% for p190, depending on quality and quantity of the isolated RNA and absence of interfering substances. Log reduction score and percent abnormal are reported, and longitudinal data will appear as a NeoTRACK Result on the report. Testing is New York approved for p210 and p190 only. p230 testing may be ordered as a reflex if p210 and p190 are negative, or as a stand-alone test, BCR-ABL1 Non-Standard p230. For p230, results are reported as percent abnormal.